Endocrine therapy resistance: Current status, possible mechanisms and overcoming strategies

Anti-Cancer Agents in Medicinal Chemistry

Volumn 13, Issue 3, 2013, Pages 464-475

  Chang, Jinjia ^a   Fan, Weimin ^a,b  

^a ZHEJIANG UNIVERSITY   (China)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

AIs; Endocrine resistance; Endocrine therapy; Estrogen receptor; HER2; SERDs; SERMs

Indexed keywords

ANASTROZOLE; ANTIESTROGEN; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIN D1; DNA METHYLTRANSFERASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; EVEROLIMUS; EXEMESTANE; FADROZOLE; FULVESTRANT; GEFITINIB; HISTONE DEACETYLASE INHIBITOR; LAPATINIB; LETROZOLE; MEGESTROL ACETATE; MESSENGER RNA; PACLITAXEL; PLACEBO; RALOXIFENE; ROMIDEPSIN; TAMOXIFEN; TEMSIROLIMUS; TOREMIFENE; TRASTUZUMAB; UNINDEXED DRUG; VORINOSTAT;

BREAST CANCER; BREAST METASTASIS; BREAST TUMOR; CANCER HORMONE THERAPY; CARDIOTOXICITY; CELL CYCLE ARREST; CELL PROLIFERATION; CELL SURVIVAL; DNA METHYLATION; DRUG EFFICACY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; GASTROINTESTINAL TOXICITY; GENE DELETION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; NONHUMAN; OSTEOPOROSIS; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POINT MUTATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVIEW; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMORADIOTHERAPY, ADJUVANT; DRUG RESISTANCE, NEOPLASM; ESTROGEN ANTAGONISTS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOPLASMS, HORMONE-DEPENDENT; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SIGNAL TRANSDUCTION;

EID: 84876720503     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/1871520611313030009     Document Type: Review

References (139)

1. Dickson, R. B.; Lippman, M. E., Control of human breast cancer by estrogen, growth factors, and oncogenes. Cancer Treat Res., 1988, 40, 119-165.
2. Yamashita, H., Current research topics in endocrine therapy for breast cancer. Int. J. Clin. Oncol., 2008, 13(5), 380-383.
3. Sui, M.; Chen, F.; Chen, Z.; Fan, W., Glucocorticoids interfere with therapeutic efficacy of paclitaxel against human breast and ovarian xenograft tumors. Int. J. Cancer, 2006, 119(3), 712-717.
4. Sui, M.; Huang, Y.; Park, B. H.; Davidson, N. E.; Fan, W., Estrogen receptor alpha mediates breast cancer cell resistance to paclitaxel through inhibition of apoptotic cell death. Cancer Res, 2007, 67(11), 5337-5344.
5. Sui, M.; Jiang, D.; Hinsch, C.; Fan, W., Fulvestrant (ICI 182,780) sensitizes breast cancer cells expressing estrogen receptor alpha to vinblastine and vinorelbine. Breast Cancer Res. Treat, 2009, 121(2), 335-345.
6. Lippman, M. E.; Allegra, J. C.; Thompson, E. B.; Simon, R.; Barlock, A.; Green, L.; Huff, K. K.; Do, H. M.; Aitken, S. C.; Warren, R., The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. N. Engl. J. Med., 1978, 298(22), 1223-1228.
7. Zambetti, M.; Mansutti, M.; Gomez, P.; Lluch, A.; Dittrich, C.; Zamagni, C.; Ciruelos, E.; Pavesi, L.; Semiglazov, V.; De Benedictis, E.; Gaion, F.; Bari, M.; Morandi, P.; Valagussa, P.; Luca, G., Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II). Breast Cancer Res. Treat, 2011, 132(3), 843-851.
8. Tamoxifen for early breast cancer: an overview of the randomized trials. Early Breast Cancer Trialists' Collaborative Group. Lancet, 1998, 351(9114), 1451-1467.
9. Osborne, C. K., Tamoxifen in the treatment of breast cancer. N. Engl. J. Med., 1998, 339(22), 1609-1618.
10. Iqbal, J.; Ginsburg, O. M.; Wijeratne, T. D.; Howell, A.; Evans, G.; Sestak, I.; Narod, S. A., Endometrial cancer and venous thromboembolism in women under age 50 who take tamoxifen for prevention of breast cancer: A systematic review. Cancer Treat Rev., 2011, 38(4), 318-328.
11. Cummings, S. R.; Eckert, S.; Krueger, K. A.; Grady, D.; Powles, T. J.; Cauley, J. A.; Norton, L.; Nickelsen, T.; Bjarnason, N. H.; Morrow, M.; Lippman, M. E.; Black, D.; Glusman, J. E.; Costa, A.; Jordan, V. C., The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA, 1999, 281(23), 2189-2197.
12. Heuser, T.; Rink, T.; Weller, E.; Fitz, H.; Zippel, H. H.; Kreienberg, R.; Kuhn, T., Impact of the axillary nodal status on sentinel node mapping in breast cancer and its relevance for technical proceeding. Breast Cancer Res. Treat, 2001, 67(2), 125-132.
13. Howell, S. J.; Johnston, S. R.; Howell, A., The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer. Best Pract. Res. Clin. Endocrinol. Metab., 2004, 18(1), 47-66.
14. Addo, S.; Yates, R. A.; Laight, A., A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers. Br. J. Cancer, 2002, 87(12), 1354-1359.
15. Mouridsen, H.; Gershanovich, M.; Sun, Y.; Perez-Carrion, R.; Boni, C.; Monnier, A.; Apffelstaedt, J.; Smith, R.; Sleeboom, H. P.; Janicke, F.; Pluzanska, A.; Dank, M.; Becquart, D.; Bapsy, P. P.; Salminen, E.; Snyder, R.; Lassus, M.; Verbeek, J. A.; Staffler, B.; Chaudri-Ross, H. A.; Dugan, M., Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J. Clin. Oncol., 2001, 19 (10), 2596-2606.
16. Bonneterre, J.; Thurlimann, B.; Robertson, J. F.; Krzakowski, M.; Mauriac, L.; Koralewski, P.; Vergote, I.; Webster, A.; Steinberg, M.; von Euler, M., Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J. Clin. Oncol., 2000, 18 (22), 3748-3757.
17. Nabholtz, J. M.; Buzdar, A.; Pollak, M.; Harwin, W.; Burton, G.; Mangalik, A.; Steinberg, M.; Webster, A.; von Euler, M., Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J. Clin. Oncol., 2000, 18(22), 3758-3767.
18. Masuda, N.; Sagara, Y.; Kinoshita, T.; Iwata, H.; Nakamura, S.; Yanagita, Y.; Nishimura, R.; Iwase, H.; Kamigaki, S.; Takei, H.; Noguchi, S., Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial. Lancet Oncol., 2012, 13 (4), 345-352.
19. Goss, P. E.; Ingle, J. N.; Ales-Martinez, J. E.; Cheung, A. M.; Chlebowski, R. T.; Wactawski-Wende, J.; McTiernan, A.; Robbins, J.; Johnson, K. C.; Martin, L. W.; Winquist, E.; Sarto, G. E.; Garber, J. E.; Fabian, C. J.; Pujol, P.; Maunsell, E.; Farmer, P.; Gelmon, K. A.; Tu, D.; Richardson, H., Exemestane for breast-cancer prevention in postmenopausal women. N. Engl. J. Med., 2012, 364(25), 2381-2391.
20. Dixon, J. M.; Renshaw, L.; Bellamy, C.; Stuart, M.; Hoctin-Boes, G.; Miller, W. R., The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study. Clin. Cancer Res., 2000, 6(6), 2229-2235.
21. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet, 2005, 365(9472), 1687-1717.
22. Gradishar, W. J., Tamoxifen--what next? Oncologist, 2004, 9(4), 378-384.
23. Strasser-Weippl, K.; Goss, P. E., Advances in adjuvant hormonal therapy for postmenopausal women. J. Clin. Oncol., 2005, 23(8), 1751-1759.
24. Robertson, J. F., Faslodex (ICI 182, 780), a novel estrogen receptor downregulator--future possibilities in breast cancer. J. Steroid Biochem. Mol. Biol., 2001, 79(1-5), 209-212.
25. Robertson, J. F.; Osborne, C. K.; Howell, A.; Jones, S. E.; Mauriac, L.; Ellis, M.; Kleeberg, U. R.; Come, S. E.; Vergote, I.; Gertler, S.; Buzdar, A.; Webster, A.; Morris, C., Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer, 2003, 98(2), 229-238.
26. Jelovac, D.; Macedo, L.; Goloubeva, O. G.; Handratta, V.; Brodie, A. M., Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model. Cancer Res., 2005, 65 (12), 5439-5444.
27. Brodie, A.; Sabnis, G., Adaptive changes result in activation of alternate signaling pathways and acquisition of resistance to aromatase inhibitors. Clin. Cancer Res., 2011, 17(13), 4208-4213.
28. Sommer, A.; Hoffmann, J.; Lichtner, R. B.; Schneider, M. R.; Parczyk, K., Studies on the development of resistance to the pure antiestrogen Faslodex in three human breast cancer cell lines. J. Steroid Biochem. Mol. Biol., 2003, 85(1), 33-47.
29. Johnston, S. J.; Cheung, K. L., Fulvestrant - a novel endocrine therapy for breast cancer. Curr Med Chem, 2010, 17(10), 902-914.
30. Speirs, V.; Parkes, A. T.; Kerin, M. J.; Walton, D. S.; Carleton, P. J.; Fox, J. N.; Atkin, S. L., Coexpression of estrogen receptor alpha and beta: poor prognostic factors in human breast cancer? Cancer Res., 1999, 59(3), 525-528.
31. Hopp, T. A.; Weiss, H. L.; Parra, I. S.; Cui, Y.; Osborne, C. K.; Fuqua, S. A., Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer. Clin Cancer Res., 2004, 10(22), 7490-7499.
32. Borgquist, S.; Holm, C.; Stendahl, M.; Anagnostaki, L.; Landberg, G.; Jirstrom, K., Oestrogen receptors alpha and beta show different associations to clinicopathological parameters and their co-expression might predict a better response to endocrine treatment in breast cancer. J. Clin. Pathol., 2008, 61(2), 197-203.
33. Chen, B.; Gajdos, C.; Dardes, R.; Kidwai, N.; Johnston, S. R.; Dowsett, M.; Jordan, V. C., Potential of endogenous estrogen receptor beta to influence the selective ER modulator ERbeta complex. Int. J. Oncol., 2005, 27 (2), 327-335.
34. Murphy, L. C.; Peng, B.; Lewis, A.; Davie, J. R.; Leygue, E.; Kemp, A.; Ung, K.; Vendetti, M.; Shiu, R., Inducible upregulation of oestrogen receptor-beta1 affects oestrogen and tamoxifen responsiveness in MCF7 human breast cancer cells. J. Mol. Endocrinol., 2005, 34(2), 553-566.
35. Esslimani-Sahla, M.; Simony-Lafontaine, J.; Kramar, A.; Lavaill, R.; Mollevi, C.; Warner, M.; Gustafsson, J. A.; Rochefort, H., Estrogen receptor beta (ER beta) level but not its ER beta cx variant helps to predict tamoxifen resistance in breast cancer. Clin. Cancer Res., 2004, 10(17), 5769-5776.
36. Mann, S.; Laucirica, R.; Carlson, N.; Younes, P. S.; Ali, N.; Younes, A.; Li, Y.; Younes, M., Estrogen receptor beta expression in invasive breast cancer. Hum. Pathol., 2001, 32(1), 113-118.
37. Khan, S. A.; Rogers, M. A.; Khurana, K. K.; Meguid, M. M.; Numann, P. J., Estrogen receptor expression in benign breast epithelium and breast cancer risk. J. Natl. Cancer Inst., 1998, 90 (1), 37-42.
38. Smith, I. E.; Dowsett, M., Aromatase inhibitors in breast cancer. N. Engl. J. Med., 2003, 348(24), 2431-2442.
39. Ottaviano, Y. L.; Issa, J. P.; Parl, F. F.; Smith, H. S.; Baylin, S. B.; Davidson, N. E., Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res., 1994, 54(10), 2552-2555.
40. Lapidus, R. G.; Ferguson, A. T.; Ottaviano, Y. L.; Parl, F. F.; Smith, H. S.; Weitzman, S. A.; Baylin, S. B.; Issa, J. P.; Davidson, N. E., Methylation of estrogen and progesterone receptor gene 5' CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors. Clin. Cancer Res., 1996, 2(5), 805-810.
41. Robertson, K. D.; Ait-Si-Ali, S.; Yokochi, T.; Wade, P. A.; Jones, P. L.; Wolffe, A. P., DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters. Nat. Genet., 2000, 25(3), 338-342.
42. Rountree, M. R.; Bachman, K. E.; Baylin, S. B., DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci. Nat. Genet., 2000, 25(3), 269-277.
43. Yang, X.; Ferguson, A. T.; Nass, S. J.; Phillips, D. L.; Butash, K. A.; Wang, S. M.; Herman, J. G.; Davidson, N. E., Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition. Cancer Res., 2000, 60(24), 6890-6894.
44. Fan, J.; Yin, W. J.; Lu, J. S.; Wang, L.; Wu, J.; Wu, F. Y.; Di, G. H.; Shen, Z. Z.; Shao, Z. M., ER alpha negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor. J. Cancer Res. Clin. Oncol., 2008, 134(8), 883-890.
45. Davis, T.; Kennedy, C.; Chiew, Y. E.; Clarke, C. L.; de Fazio, A., Histone deacetylase inhibitors decrease proliferation and modulate cell cycle gene expression in normal mammary epithelial cells. Clin. Cancer Res., 2000, 6(11), 4334-4342.
46. Graham, M. L., 2nd; Krett, N. L.; Miller, L. A.; Leslie, K. K.; Gordon, D. F.; Wood, W. M.; Wei, L. L.; Horwitz, K. B., T47DCO cells, genetically unstable and containing estrogen receptor mutations, are a model for the progression of breast cancers to hormone resistance. Cancer Res., 1990, 50(19), 6208-6217.
47. Wolf, D. M.; Jordan, V. C., The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain. Breast Cancer Res Treat, 1994, 31(1), 129-138.
48. Herynk, M. H.; Fuqua, S. A., Estrogen receptor mutations in human disease. Endocr. Rev., 2004, 25(6), 869-898.
49. McGuire, W. L., Hormone receptors: their role in predicting prognosis and response to endocrine therapy. Semin Oncol., 1978, 5(4), 428-433.
50. Bardou, V. J.; Arpino, G.; Elledge, R. M.; Osborne, C. K.; Clark, G. M., Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J. Clin. Oncol., 2003, 21(10), 1973-1979.
51. Elledge, R. M.; Green, S.; Pugh, R.; Allred, D. C.; Clark, G. M.; Hill, J.; Ravdin, P.; Martino, S.; Osborne, C. K., Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study. Int. J Cancer, 2000, 89(2), 111-117.
52. Ravdin, P. M.; Green, S.; Dorr, T. M.; McGuire, W. L.; Fabian, C.; Pugh, R. P.; Carter, R. D.; Rivkin, S. E.; Borst, J. R.; Belt, R. J. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J. Clin. Oncol., 1992, 10(8), 1284-1291.
53. Park, S.; Park, H. S.; Koo, J. S.; Yang, W. I.; Kim, S. I.; Park, B. W., Higher expression of androgen receptor is a significant predictor for better endocrine-responsiveness in estrogen receptor-positive breast cancers. Breast Cancer Res. Treat, 2012, 133(1), 311-320.
54. Aapro, M. S.; Forbes, J. F., Three years' follow-up from the ATAC trial is sufficient to change clinical practice: a debate. Breast Cancer Res. Treat, 2003, 80 Suppl 1, S3-S11; discussion S13-8.
55. Ellis, M. J.; Coop, A.; Singh, B.; Mauriac, L.; Llombert-Cussac, A.; Janicke, F.; Miller, W. R.; Evans, D. B.; Dugan, M.; Brady, C.; Quebe-Fehling, E.; Borgs, M., Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J. Clin. Oncol., 2001, 19(18), 3808-3816.
56. Dowsett, M., Designing the future shape of breast cancer diagnosis, prognosis and treatment. Breast Cancer Res. Treat, 2004, 87 Suppl 1, S27-S29.
57. Balleine, R. L.; Earl, M. J.; Greenberg, M. L.; Clarke, C. L., Absence of progesterone receptor associated with secondary breast cancer in postmenopausal women. Br. J. Cancer, 1999, 79(9-10), 1564-15671.
58. Cui, X.; Zhang, P.; Deng, W.; Oesterreich, S.; Lu, Y.; Mills, G. B.; Lee, A. V., Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer. Mol. Endocrinol., 2003, 17(4), 575-588.
59. Petz, L. N.; Ziegler, Y. S.; Schultz, J. R.; Nardulli, A. M., Fos and Jun inhibit estrogen-induced transcription of the human progesterone receptor gene through an activator protein-1 site. Mol. Endocrinol., 2004, 18(3), 521-532.
60. Tovey, S.; Dunne, B.; Witton, C. J.; Forsyth, A.; Cooke, T. G.; Bartlett, J. M., Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer? Clin. Cancer Res., 2005, 11(13), 4835-4842.
61. Arpino, G.; Green, S. J.; Allred, D. C.; Lew, D.; Martino, S.; Osborne, C. K.; Elledge, R. M., HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. Clin. Cancer Res., 2004, 10(17), 5670-5676.
62. De Placido, S.; De Laurentiis, M.; Carlomagno, C.; Gallo, C.; Perrone, F.; Pepe, S.; Ruggiero, A.; Marinelli, A.; Pagliarulo, C.; Panico, L.; Pettinato, G.; Petrella, G.; Bianco, A. R., Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer. Clin. Cancer Res., 2003, 9(3), 1039-1046.
63. Dowsett, M.; Harper-Wynne, C.; Boeddinghaus, I.; Salter, J.; Hills, M.; Dixon, M.; Ebbs, S.; Gui, G.; Sacks, N.; Smith, I., HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. Cancer Res., 2001, 61(23), 8452-8458.
64. Sachdev, J. C.; Jahanzeb, M., Blockade of the HER family of receptors in the treatment of HER2-positive metastatic breast cancer. Clin. Breast Cancer, 2011, 12(1), 19-29.
65. Shyamala, G.; Schweitzer, M.; Ullrich, S. J., Relationship between 90-kilodalton heat shock protein, estrogen receptor, and progesterone receptor in human mammary tumors. Breast Cancer Res. Treat, 1993, 26(1), 95-100.
66. Pietras, R. J.; Arboleda, J.; Reese, D. M.; Wongvipat, N.; Pegram, M. D.; Ramos, L.; Gorman, C. M.; Parker, M. G.; Sliwkowski, M. X.; Slamon, D. J., HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene, 1995, 10(12), 2435-2446.
67. Parisot, J. P.; Leeding, K. S.; Hu, X. F.; DeLuise, M.; Zalcberg, J. R.; Bach, L. A., Induction of insulin-like growth factor binding protein expression by ICI 182,780 in a tamoxifen-resistant human breast cancer cell line. Breast Cancer Res. Treat, 1999, 55(3), 231-242.
68. Lipton, A.; Ali, S. M.; Leitzel, K.; Demers, L.; Harvey, H. A.; Chaudri-Ross, H. A.; Brady, C.; Wyld, P.; Carney, W., Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen. J. Clin. Oncol., 2003, 21(10), 1967-1972.
69. Benz, C. C.; Scott, G. K.; Sarup, J. C.; Johnson, R. M.; Tripathy, D.; Coronado, E.; Shepard, H. M.; Osborne, C. K., Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res. Treat, 1992, 24(2), 85-95.
70. Wakeling, A. E.; Nicholson, R. I.; Gee, J. M., Prospects for combining hormonal and nonhormonal growth factor inhibition. Clin. Cancer Res., 2001, 7(12 Suppl), 4350s-4355s; discussion 4411s-4412s.
71. Shou, J.; Massarweh, S.; Osborne, C. K.; Wakeling, A. E.; Ali, S.; Weiss, H.; Schiff, R., Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J. Natl. Cancer Inst., 2004, 96(12), 926-935.
72. Chung, Y. L.; Sheu, M. L.; Yang, S. C.; Lin, C. H.; Yen, S. H., Resistance to tamoxifen-induced apoptosis is associated with direct interaction between Her2/neu and cell membrane estrogen receptor in breast cancer. Int. J. Cancer, 2002, 97(3), 306-312.
73. Fagan, D. H.; Yee, D., Crosstalk between IGF1R and estrogen receptor signaling in breast cancer. J. Mammary Gland Biol. Neoplasia, 2008, 13(4), 423-429.
74. Baserga, R., The contradictions of the insulin-like growth factor 1 receptor. Oncogene, 2000, 19(49), 5574-5581.
75. Werner, H.; Bruchim, I., The insulin-like growth factor-I receptor as an oncogene. Arch. Physiol. Biochem., 2009, 115(2), 58-71.
76. Baserga, R., The insulin-like growth factor I receptor: a key to tumor growth? Cancer Res., 1995, 55(2), 249-252.
77. Hankinson, S. E.; Willett, W. C.; Colditz, G. A.; Hunter, D. J.; Michaud, D. S.; Deroo, B.; Rosner, B.; Speizer, F. E.; Pollak, M., Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet, 1998, 351(9113), 1393-1396.
78. Peyrat, J. P.; Bonneterre, J.; Beuscart, R.; Djiane, J.; Demaille, A., Insulin-like growth factor 1 receptors in human breast cancer and their relation to estradiol and progesterone receptors. Cancer Res., 1988, 48(22), 6429-6433.
79. Kiaris, H.; Schally, A. V.; Varga, J. L., Antagonists of growth hormone-releasing hormone inhibit the growth of U-87MG human glioblastoma in nude mice. Neoplasia, 2000, 2(3), 242-250.
80. Hamelers, I. H.; Steenbergh, P. H., Interactions between estrogen and insulin-like growth factor signaling pathways in human breast tumor cells. Endocr. Relat. Cancer, 2003, 10(2), 331-345.
81. Lee, A. V.; Weng, C. N.; Jackson, J. G.; Yee, D., Activation of estrogen receptor-mediated gene transcription by IGF-I in human breast cancer cells. J. Endocrinol., 1997, 152(1), 39-47.
82. Maxwell, P.; van den Berg, H. W., Changes in the secretion of insulin-like growth factor binding proteins -2 and -4 associated with the development of tamoxifen resistance and estrogen independence in human breast cancer cell lines. Cancer Lett, 1999, 139(2), 121-127.
83. Lisztwan, J.; Pornon, A.; Chen, B.; Chen, S.; Evans, D. B., The aromatase inhibitor letrozole and inhibitors of insulin-like growth factor I receptor synergistically induce apoptosis in in vitro models of estrogen-dependent breast cancer. Breast Cancer Res., 2008, 10(4), R56.
84. Law, J. H.; Habibi, G.; Hu, K.; Masoudi, H.; Wang, M. Y.; Stratford, A. L.; Park, E.; Gee, J. M.; Finlay, P.; Jones, H. E.; Nicholson, R. I.; Carboni, J.; Gottardis, M.; Pollak, M.; Dunn, S. E., Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res., 2008, 68(24), 10238-10246.
85. Zhang, Y.; Moerkens, M.; Ramaiahgari, S.; de Bont, H.; Price, L.; Meerman, J.; van de Water, B., Elevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK/ERK and PI3K/Akt signaling routes. Breast Cancer Res, 2011, 13(3), R52.
86. Massarweh, S.; Osborne, C. K.; Creighton, C. J.; Qin, L.; Tsimelzon, A.; Huang, S.; Weiss, H.; Rimawi, M.; Schiff, R., Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res., 2008, 68(3), 826-833.
87. Yue, W.; Fan, P.; Wang, J.; Li, Y.; Santen, R. J., Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells. J. Steroid Biochem. Mol. Biol., 2007, 106(1-5), 102-110.
88. Arpino, G.; De Angelis, C.; Giuliano, M.; Giordano, A.; Falato, C.; De Laurentiis, M.; De Placido, S., Molecular mechanism and clinical implications of endocrine therapy resistance in breast cancer. Oncology, 2009, 77 Suppl 1, 23-37.
89. Chong, K.; Subramanian, A.; Sharma, A.; Mokbel, K., Measuring IGF-1, ER-alpha and EGFR expression can predict tamoxifen-resistance in ER-positive breast cancer. Anticancer Res., 2011, 31(1), 23-32.
90. Milano, A.; Dal Lago, L.; Sotiriou, C.; Piccart, M.; Cardoso, F., What clinicians need to know about antioestrogen resistance in breast cancer therapy. Eur. J. Cancer, 2006, 42(16), 2692-2705.
91. Pink, J. J.; Bilimoria, M. M.; Assikis, J.; Jordan, V. C., Irreversible loss of the oestrogen receptor in T47D breast cancer cells following prolonged oestrogen deprivation. Br. J. Cancer, 1996, 74(8), 1227-1236.
92. Stoica, A.; Saceda, M.; Fakhro, A.; Joyner, M.; Martin, M. B., Role of insulin-like growth factor-I in regulating estrogen receptor-alpha gene expression. J. Cell Biochem, 2000, 76(4), 605-614.
93. Stoica, A.; Saceda, M.; Doraiswamy, V. L.; Coleman, C.; Martin, M. B., Regulation of estrogen receptor-alpha gene expression by epidermal growth factor. J. Endocrinol., 2000, 165(2), 371-378.
94. Steeg, P. S.; Zhou, Q., Cyclins and breast cancer. Breast Cancer Res. Treat, 1998, 52(1-3), 17-28.
95. Nielsen, N. H.; Arnerlov, C.; Emdin, S. O.; Landberg, G., Cyclin E overexpression, a negative prognostic factor in breast cancer with strong correlation to oestrogen receptor status. Br. J. Cancer, 1996, 74(6), 874-880.
96. Buckley, M. F.; Sweeney, K. J.; Hamilton, J. A.; Sini, R. L.; Manning, D. L.; Nicholson, R. I.; deFazio, A.; Watts, C. K.; Musgrove, E. A.; Sutherland, R. L., Expression and amplification of cyclin genes in human breast cancer. Oncogene, 1993, 8(8), 2127-2133.
97. Butt, A. J.; McNeil, C. M.; Musgrove, E. A.; Sutherland, R. L., Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E. Endocr. Relat. Cancer, 2005, 12 Suppl 1, S47-S59.
98. Wilcken, N. R.; Prall, O. W.; Musgrove, E. A.; Sutherland, R. L., Inducible overexpression of cyclin D1 in breast cancer cells reverses the growth-inhibitory effects of antiestrogens. Clin. Cancer Res., 1997, 3(6), 849-854.
99. Kilker, R. L.; Hartl, M. W.; Rutherford, T. M.; Planas-Silva, M. D., Cyclin D1 expression is dependent on estrogen receptor function in tamoxifen-resistant breast cancer cells. J. Steroid Biochem. Mol. Biol., 2004, 92(1-2), 63-71.
100. Hui, R.; Finney, G. L.; Carroll, J. S.; Lee, C. S.; Musgrove, E. A.; Sutherland, R. L., Constitutive overexpression of cyclin D1 but not cyclin E confers acute resistance to antiestrogens in T-47D breast cancer cells. Cancer Res., 2002, 62(23), 6916-6923.
101. Coqueret, O., Linking cyclins to transcriptional control. Gene, 2002, 299(1-2), 35-55.
102. Kenny, F. S.; Hui, R.; Musgrove, E. A.; Gee, J. M.; Blamey, R. W.; Nicholson, R. I.; Sutherland, R. L.; Robertson, J. F., Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer. Clin. Cancer Res., 1999, 5(8), 2069-2076.
103. Stendahl, M.; Kronblad, A.; Ryden, L.; Emdin, S.; Bengtsson, N. O.; Landberg, G., Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients. Br. J. Cancer, 2004, 90(10), 1942-1948.
104. Pacilio, C.; Germano, D.; Addeo, R.; Altucci, L.; Petrizzi, V. B.; Cancemi, M.; Cicatiello, L.; Salzano, S.; Lallemand, F.; Michalides, R. J.; Bresciani, F.; Weisz, A., Constitutive overexpression of cyclin D1 does not prevent inhibition of hormone-responsive human breast cancer cell growth by antiestrogens. Cancer Res., 1998, 58(5), 871-876.
105. Bindels, E. M.; Lallemand, F.; Balkenende, A.; Verwoerd, D.; Michalides, R., Involvement of G1/S cyclins in estrogen-independent proliferation of estrogen receptor-positive breast cancer cells. Oncogene, 2002, 21(53), 8158-8165.
106. Dhillon, N. K.; Mudryj, M., Ectopic expression of cyclin E in estrogen responsive cells abrogates antiestrogen mediated growth arrest. Oncogene, 2002, 21(30), 4626-4634.
107. Akli, S.; Zheng, P. J.; Multani, A. S.; Wingate, H. F.; Pathak, S.; Zhang, N.; Tucker, S. L.; Chang, S.; Keyomarsi, K., Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer. Cancer Res., 2004, 64(9), 3198-3208.
108. Musgrove, E. A.; Sergio, C. M.; Loi, S.; Inman, C. K.; Anderson, L. R.; Alles, M. C.; Pinese, M.; Caldon, C. E.; Schutte, J.; Gardiner-Garden, M.; Ormandy, C. J.; McArthur, G.; Butt, A. J.; Sutherland, R. L., Identification of functional networks of estrogen-and c-Myc-responsive genes and their relationship to response to tamoxifen therapy in breast cancer. PLoS One, 2008, 3(8), e2987.
109. Bosco, E. E.; Wang, Y.; Xu, H.; Zilfou, J. T.; Knudsen, K. E.; Aronow, B. J.; Lowe, S. W.; Knudsen, E. S., The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer. J. Clin. Invest., 2007, 117(1), 218-228.
110. Span, P. N.; Tjan-Heijnen, V. C.; Manders, P.; Beex, L. V.; Sweep, C. G., Cyclin-E is a strong predictor of endocrine therapy failure in human breast cancer. Oncogene, 2003, 22(31), 4898-4904.
111. Kim, H. K.; Park, I. A.; Heo, D. S.; Noh, D. Y.; Choe, K. J.; Bang, Y. J.; Kim, N. K., Cyclin E overexpression as an independent risk factor of visceral relapse in breast cancer. Eur. J. Surg. Oncol., 2001, 27(5), 464-471.
112. Keyomarsi, K.; Tucker, S. L.; Buchholz, T. A.; Callister, M.; Ding, Y.; Hortobagyi, G. N.; Bedrosian, I.; Knickerbocker, C.; Toyofuku, W.; Lowe, M.; Herliczek, T. W.; Bacus, S. S., Cyclin E and survival in patients with breast cancer. N. Engl. J. Med., 2002, 347(20), 1566-1575.
113. Bukholm, I. R.; Bukholm, G.; Nesland, J. M., Over-expression of cyclin A is highly associated with early relapse and reduced survival in patients with primary breast carcinomas. Int. J. Cancer, 2001, 93(2), 283-287.
114. Rudolph, P.; Kuhling, H.; Alm, P.; Ferno, M.; Baldetorp, B.; Olsson, H.; Parwaresch, R., Differential prognostic impact of the cyclins E and B in premenopausal and postmenopausal women with lymph node-negative breast cancer. Int. J. Cancer, 2003, 105(5), 674-680.
115. Kaufman, B.; Mackey, J. R.; Clemens, M. R.; Bapsy, P. P.; Vaid, A.; Wardley, A.; Tjulandin, S.; Jahn, M.; Lehle, M.; Feyereislova, A.; Revil, C.; Jones, A., Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J. Clin. Oncol., 2009, 27(33), 5529-5537.
116. Marcom, P. K.; Isaacs, C.; Harris, L.; Wong, Z. W.; Kommarreddy, A.; Novielli, N.; Mann, G.; Tao, Y.; Ellis, M. J., The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Res. Treat, 2007, 102(1), 43-49.
117. Johnston, S.; Pippen, J., Jr.; Pivot, X.; Lichinitser, M.; Sadeghi, S.; Dieras, V.; Gomez, H. L.; Romieu, G.; Manikhas, A.; Kennedy, M. J.; Press, M. F.; Maltzman, J.; Florance, A.; O'Rourke, L.; Oliva, C.; Stein, S.; Pegram, M., Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J. Clin. Oncol., 2009, 27(33), 5538-5546.
118. Faridi, J.; Wang, L.; Endemann, G.; Roth, R. A., Expression of constitutively active Akt-3 in MCF-7 breast cancer cells reverses the estrogen and tamoxifen responsivity of these cells in vivo. Clin. Cancer Res., 2003, 9(8), 2933-2939.
119. Clark, A. S.; West, K.; Streicher, S.; Dennis, P. A., Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol. Cancer Ther., 2002, 1(9), 707-717.
120. Boulay, A.; Rudloff, J.; Ye, J.; Zumstein-Mecker, S.; O'Reilly, T.; Evans, D. B.; Chen, S.; Lane, H. A. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res., 2005, 11(14), 5319-5328.
121. Treeck, O.; Wackwitz, B.; Haus, U.; Ortmann, O., Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells. Gynecol. Oncol., 2006, 102(2), 292-299.
122. Beeram, M.; Tan, Q. T.; Tekmal, R. R.; Russell, D.; Middleton, A.; DeGraffenried, L. A. Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling. Ann. Oncol., 2007, 18(8), 1323-1328.
123. Baselga, J.; Semiglazov, V.; van Dam, P.; Manikhas, A.; Bellet, M.; Mayordomo, J.; Campone, M.; Kubista, E.; Greil, R.; Bianchi, G.; Steinseifer, J.; Molloy, B.; Tokaji, E.; Gardner, H.; Phillips, P.; Stumm, M.; Lane, H. A.; Dixon, J. M.; Jonat, W.; Rugo, H. S., Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J. Clin. Oncol., 2009, 27(16), 2630-2637.
124. Sadler, T. M.; Gavriil, M.; Annable, T.; Frost, P.; Greenberger, L. M.; Zhang, Y. Combination therapy for treating breast cancer using antiestrogen, ERA-923, and the mammalian target of rapamycin inhibitor, temsirolimus. Endocr. Relat. Cancer, 2006, 13(3), 863-873.
125. Chan, S.; Scheulen, M. E.; Johnston, S.; Mross, K.; Cardoso, F.; Dittrich, C.; Eiermann, W.; Hess, D.; Morant, R.; Semiglazov, V.; Borner, M.; Salzberg, M.; Ostapenko, V.; Illiger, H. J.; Behringer, D.; Bardy-Bouxin, N.; Boni, J.; Kong, S.; Cincotta, M.; Moore, L., Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J. Clin. Oncol., 2005, 23(23), 5314-5322.
126. Ellis, M. J.; Gao, F.; Dehdashti, F.; Jeffe, D. B.; Marcom, P. K.; Carey, L. A.; Dickler, M. N.; Silverman, P.; Fleming, G. F.; Kommareddy, A.; Jamalabadi-Majidi, S.; Crowder, R.; Siegel, B. A., Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. JAMA, 2009, 302(7), 774-780.
127. Lonning, P. E.; Taylor, P. D.; Anker, G.; Iddon, J.; Wie, L.; Jorgensen, L. M.; Mella, O.; Howell, A., High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Res. Treat, 2001, 67(2), 111-116.
128. Carter, A. C.; Sedransk, N.; Kelley, R. M.; Ansfield, F. J.; Ravdin, R. G.; Talley, R. W.; Potter, N. R., Diethylstilbestrol: recommended dosages for different categories of breast cancer patients. Report of the Cooperative Breast Cancer Group. JAMA, 1977, 237(19), 2079-2088.
129. Lewis, J. S.; Meeke, K.; Osipo, C.; Ross, E. A.; Kidawi, N.; Li, T.; Bell, E.; Chandel, N. S.; Jordan, V. C., Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation. J. Natl. Cancer Inst., 2005, 97(23), 1746-1759.
130. Song, R. X.; Mor, G.; Naftolin, F.; McPherson, R. A.; Song, J.; Zhang, Z.; Yue, W.; Wang, J.; Santen, R. J., Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol. J. Nat. Cancer Inst., 2001, 93(22), 1714-1723.
131. Ariazi, E. A.; Cunliffe, H. E.; Lewis-Wambi, J. S.; Slifker, M. J.; Willis, A. L.; Ramos, P.; Tapia, C.; Kim, H. R.; Yerrum, S.; Sharma, C. G.; Nicolas, E.; Balagurunathan, Y.; Ross, E. A.; Jordan, V. C., Estrogen induces apoptosis in estrogen deprivation-resistant breast cancer through stress responses as identified by global gene expression across time. Proc. Natl. Acad. Sci. U.S. A., 2011, 108(47), 18879-18886.
132. Jordan, V. C.; Ford, L. G., Paradoxical clinical effect of estrogen on breast cancer risk: a new biology of estrogen-induced apoptosis. Cancer Prev Res (Phila), 2011, 4(5), 633-637.
133. Sharma, D.; Blum, J.; Yang, X.; Beaulieu, N.; Macleod, A. R.; Davidson, N. E., Release of methyl CpG binding proteins and histone deacetylase 1 from the Estrogen receptor alpha (ER) promoter upon reactivation in ER-negative human breast cancer cells. Mol. Endocrinol., 2005, 19(7), 1740-1751.
134. Piekarz, R. L.; Frye, R.; Turner, M.; Wright, J. J.; Allen, S. L.; Kirschbaum, M. H.; Zain, J.; Prince, H. M.; Leonard, J. P.; Geskin, L. J.; Reeder, C.; Joske, D.; Figg, W. D.; Gardner, E. R.; Steinberg, S. M.; Jaffe, E. S.; Stetler-Stevenson, M.; Lade, S.; Fojo, A. T.; Bates, S. E., Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J.Clin. Oncol, 2009, 27(32), 5410-5417.
135. Olsen, E. A.; Kim, Y. H.; Kuzel, T. M.; Pacheco, T. R.; Foss, F. M.; Parker, S.; Frankel, S. R.; Chen, C.; Ricker, J. L.; Arduino, J. M.; Duvic, M., Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J.Clin.Oncol., 2007, 25(21), 3109-3115.
136. Mei, S.; Ho, A. D.; Mahlknecht, U., Role of histone deacetylase inhibitors in the treatment of cancer (Review). Int. J. Oncol., 2004, 25(6), 1509-1519.
137. Martinez-Outschoorn, U. E.; Goldberg, A.; Lin, Z.; Ko, Y. H.; Flomenberg, N.; Wang, C.; Pavlides, S.; Pestell, R. G.; Howell, A.; Sotgia, F.; Lisanti, M. P., Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells. Cancer Biol. Ther., 2011, 12(10), 924-938.
138. Berstein, L. M.; Yue, W.; Wang, J. P.; Santen, R. J., Isolated and combined action of tamoxifen and metformin in wild-type, tamoxifen-resistant, and estrogen-deprived MCF-7 cells. Breast Cancer Res. Treat, 2010, 128(1), 109-117.
139. Goodwin, P. J.; Stambolic, V.; Lemieux, J.; Chen, B. E.; Parulekar, W. R.; Gelmon, K. A.; Hershman, D. L.; Hobday, T. J.; Ligibel, J. A.; Mayer, I. A.; Pritchard, K. I.; Whelan, T. J.; Rastogi, P.; Shepherd, L. E., Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents. Breast Cancer Res. Treat, 2010, 126(1), 215-220.